Spyre Therapeutics to Participate in Upcoming Investor Conferences
Spyre Therapeutics (SYRE) will participate in four investor conferences in London and Miami during November and December 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Spyre Therapeutics (SYRE) will participate in four investor conferences in London and Miami during November and December 2026.
Management will attend UBS on November 16, Jefferies on November 17, Evercore on December 1 and Citi on December 2. The team will also host one-on-one investor meetings. Live audio webcasts and replays will be available on Spyre's investor events website.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that management will participate in the following upcoming investor conferences in November and December:
Event: UBS Global Biopharma Conference – London
Date: Monday, November 16, 2026
Fireside Time: 1:20 pm GMT
Event: Jefferies Global Healthcare Conference – London
Date: Tuesday, November 17, 2026
Fireside Time: 3:00 pm GMT
Event: 9th Annual Evercore Healthcare Conference - Miami
Date: Tuesday, December 1, 2026
Fireside Time: 3:00 pm ET
Event: Citi’s 2026 Global Healthcare Conference - Miami
Date: Wednesday, December 2, 2026
Fireside Time: 9:40 am ET
Members of the Spyre management team will also host one-on-one investor meetings during the conferences.
Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F as well as rational combination programs.
For more information, visit Spyre's website at www.spyre.com.
For Investors:
Eric McIntyre, Spyre Therapeutics
SVP of Finance and Investor Relations
Eric.mcintyre@spyre.com
